Several Indian pharmaceutical companies are getting ready to launch cost-effective versions of the popular weight-loss and diabetes drug, semaglutide, once its patent expires in 2026. Semaglutide is sold globally by Danish company Novo Nordisk under brand names like Ozempic, Wegovy, and Rybelsus. This move could change the way people access these drugs, especially in countries